approv fda pt
view expect fulphila approv pend biosimilar
approv creat signific headwind neulasta sale
neulasta franchis risk today market close mylan/biocon
announc biosimilar neulasta pegfilgrastim-jmbd
brand name fulphila approv fda use patient
nonmyeloid cancer receiv myelosuppress chemotherapi
reduc durat febril neutropenia decreas chanc
infect see randal stanicki note fulphila
first biosimilar version neulasta approv fda
usa plan commerci launch fulphila come
week seen signific uptak neulasta onpro injector
sinc launch growth neulasta
usa come onpro potenti protect
initi biosimilar entri howev anticip weak
question surround today approv revis neulasta
estim slightli downward result pt reduct
revis neulasta estim downward fulphila approv
revis neulasta us estim slightli downward
well street estim
revis neulasta estim vs
street estim prior model assum biosimilar/pr
eros begin yr/yr declin
neulasta biosimilar competit focu shift coheru apotex
regulatori updat next neulasta biosimilar updat come
coheru novemb bsufa action date ahead later
updat competitor nv apotex behind
develop see usa fda approv biosimilar increas
competit potenti price headwind neulasta sale
valu usd unless otherwis note
price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
see limit forward growth emerg
pipelin yet fill shoe amgn matur product
eros see inexpens biotech compani
rel basi like dividend perspect
steadi cash flow despit headwind base busi
despit see risk amgn recent near-
term product launch cgrp humira biosimilar
upsid slower product eros remain
sidelin
biosimilar remain major part valuationw see
amgn intern pipelin biosimilar major revenu
ep driver though remain slightli cautiou
street launch time view recent setback
humira biosimilar indic challeng launch
environ initi anticip model amgn
biosimilar launch remicad rituxan avastin
herceptin humira see launch ahead
upsid model
launch repatha upcom
focu emerg pipelin becom construct
launch
omecamtiv parsabiv key driver off-set base busi
eros see repatha uptak signific driver
close monitor rx share follow posit long-
risk greater-than-expect competit core
busi franchis lower-than-expect uptak
grow busi develop regulatori setback
bloomberg capit market estim upside/downside/target
valu dcf basi use wacc
termin growth rate view trade
appropri valu forward price-to-earnings basi vs peer similar
growth prospect discount project revenu
risk-adjust revenu pipelin product contribut
sh revenu contribut cash contribut
result price target support
sector perform rate
upsid scenario assum longer-than-
expect delay entranc biosimilar
market slower-than-expect revenu eros
base busi higher-than-expect uptak repatha
downsid scenario assum faster-than-
expect market entri biosimilar lead greater
market share eros price pressur
base busi regulatory/litig setback
biosimilar franchis continu slow uptak repatha
compani report capit market estim
total product total product product product cost expens non oper incom ebit non tax tax net ep ep ep ep exhibit dcf valuat
compani report capit market estim
discount rate equiti growth rate mm except per-shar data discount add add effect add termin biotechnolog
valu dcf basi use wacc termin growth rate
view trade appropri valu forward price-to-earnings basi vs peer
similar growth prospect discount project revenu market product
contribut discount risk-adjust revenu pipelin product contribut
revenu contribut cash contribut result
sh price target support sector perform rate
risk rate price target
factor neg influenc valuat rate greater-than-expect
competit core busi franchis lower-than-expect uptak
grow busi develop regulatori setback late-stag pipelin
global biotechnolog compani focus develop manufactur
commerci novel biotherapeut primarili cancer nephrolog inflammatori
diseas cardiovascular diseas bone diseas pioneer use
recombin dna produc world success blockbust biotech drug
compani core busi erythropoietin epo stimul agent esa
epogen aranesp neutrophil stimul neulasta franchis
obtain princip inflammatori diseas busi enbrel acquisit
immunex go forward compani primari futur growth driver repatha
